TABLE 2.
In vitro susceptibility results for cultured mycelial and yeast forms of 32 Talaromyces marneffei strains against eight antifungal agents
| Strain type (no. of isolates) and drug | MIC/MEC (μg/ml)a in mycelial form |
MIC (μg/ml)a in yeast form |
||||||
|---|---|---|---|---|---|---|---|---|
| Range | MIC50/MEC50 | MIC90/MEC90 | Geometric mean | Range | MIC50/MEC50 | MIC90/ME90 | Geometric mean | |
| All strains (32) | ||||||||
| Olorofim | 0.0005–0.001 | 0.0005 | 0.0005 | 0.0005 | 0.00025–0.002 | 0.0005 | 0.002 | 0.0007 |
| Amphotericin B | 0.5–4 | 2 | 4 | 1.9152 | 0.031–1 | 0.125 | 0.475 | 0.1331 |
| Itraconazole | ≤0.016 | 0.016 | 0.016 | 0.0160 | ≤0.016–0.031 | 0.016 | 0.016 | 0.0163 |
| Voriconazole | ≤0.016–0.063 | 0.063 | 0.063 | 0.0453 | ≤0.016–0.031 | 0.016 | 0.0295 | 0.0174 |
| Posaconazole | ≤0.016 | 0.016 | 0.016 | 0.0160 | ≤0.016 | 0.016 | 0.016 | 0.0160 |
| Caspofungin | 0.5–4 | 1 | 4 | 1.3543 | 0.25–32 | 8 | 16 | 4.5552 |
| 5-Flucytosine | 0.031–1 | 0.062 | 0.125 | 0.0755 | 0.031–2 | 0.25 | 0.95 | 0.2443 |
| Terbinafine | 0.125–0.25 | 0.125 | 0.25 | 0.1393 | 0.031–0.5 | 0.125 | 0.25 | 0.1168 |
| Clinical (17) | ||||||||
| Olorofim | 0.0005–0.001 | 0.0005 | 0.0005 | 0.0005 | 0.00025–0.002 | 0.0005 | 0.02 | 0.0007 |
| Amphotericin B | 0.5–4 | 2 | 4 | 2 | 0.031–1 | 0.125 | 0.5 | 0.1252 |
| Itraconazole | ≤0.016 | 0.016 | 0.016 | 0.016 | ≤0.016 | 0.016 | 0.016 | 0.016 |
| Voriconazole | ≤0.016–0.063 | 0.063 | 0.063 | 0.0419 | ≤0.016–0.031 | 0.016 | 0.031 | 0.0173 |
| Posaconazole | ≤0.016 | 0.016 | 0.016 | 0.016 | ≤0.016 | 0.016 | 0.016 | 0.016 |
| Caspofungin | 0.5–4 | 2 | 4 | 1.8434 | 0.25–32 | 2 | 16 | 2.6606 |
| 5-Flucytosine | 0.031–1 | 0.063 | 0.125 | 0.0834 | 0.031–2 | 0.25 | 1 | 0.2825 |
| Terbinafine | 0.125–0.25 | 0.125 | 0.25 | 0.1471 | 0.031–0.5 | 0.125 | 0.25 | 0.1252 |
| Animal (11) | ||||||||
| Olorofim | 0.0005–0.0005 | 0.0005 | 0.0005 | 0.0005 | 0.00025–0.002 | 0.0005 | 0.002 | 0.0006 |
| Amphotericin B | 1–4 | 2 | 2 | 1.7631 | 0.063–0.5 | 0.125 | 0.25 | 0.1512 |
| Itraconazole | ≤0.016 | 0.016 | 0.016 | 0.016 | ≤0.016–0.031 | 0.016 | 0.016 | 0.017 |
| Voriconazole | 0.031–0.063 | 0.063 | 0.063 | 0.0519 | ≤0.016–0.031 | 0.016 | 0.031 | 0.018 |
| Posaconazole | ≤0.016 | 0.016 | 0.016 | 0.016 | ≤0.016 | 0.016 | 0.016 | 0.016 |
| Caspofungin | 0.5–4 | 1 | 2 | 1.065 | 1–16 | 16 | 16 | 8.5203 |
| 5-Flucytosine | 0.063–0.125 | 0.063 | 0.125 | 0.0714 | 0.031–0.5 | 0.125 | 0.5 | 0.1714 |
| Terbinafine | 0.125–0.25 | 0.125 | 0.125 | 0.1331 | 0.031–0.25 | 0.063 | 0.25 | 0.0971 |
| Environmental (4) | ||||||||
| Olorofim | 0.0005–0.0005 | 0.0005 | 0.0005–0.002 | 0.0008 | ||||
| Amphotericin B | 2–2 | 2 | 0.063–0.25 | 0.1252 | ||||
| Itraconazole | ≤0.016 | 0.016 | ≤0.016 | 0.016 | ||||
| Voriconazole | 0.031–0.063 | 0.0442 | ≤0.016 | 0.016 | ||||
| Posaconazole | ≤0.016 | 0.016 | ≤0.016 | 0.016 | ||||
| Caspofungin | 0.5–1 | 0.7071 | 2–32 | 8 | ||||
| 5-Flucytosine | 0.031–0.125 | 0.0626 | 0.125–1 | 0.3536 | ||||
| Terbinafine | 0.125–0.125 | 0.125 | 0.063–0.25 | 0.1489 | ||||
MEC, minimal effective concentration; MIC50/MEC50, minimal concentration that inhibits 50% of isolates; MIC90/MEC90, minimal concentration that inhibits 90% of isolates. MECs were used for caspofungin.